serotonin agonist (5-HT receptor agonist, triptan)
Jump to navigation
Jump to search
Indications
- treatment of migraine
Contraindications
- cardiovascular disease, including uncontrolled hypertension
- migraine with brainstem or hemiplegic aura
Adverse effects
- serotonin syndrome
- reversible cerebral vasoconstriction syndrome[4]
- triptans likely increase risk of major cardiovascular events
- incidence is low in migraine patients with elevated cardiovascular risk[6]
Drug interactions
- use in combination with SSRI or SNRI probably does not increase risk of serotonin syndrome[5]
- drug interaction(s) of triptans with SNRIs
- drug interaction(s) of triptans with SSRIs
- drug interaction(s) of methylene blue with serotonin agonists
- drug interaction(s) of linezolid with serotonin agonists
More general terms
More specific terms
- almotriptan (Axert)
- eletriptan (Relpax)
- frovatriptan (Frova)
- lasmiditan (Reyvow)
- lorcaserin (Belviq)
- naratriptan (Amerge)
- rizatriptan (Maxalt, Maxalt-MLT)
- sumatriptan (Imitrex, migratriptan, Arcoiran, Sumavel DosePro)
- zolmitriptan (Zomig)
Additional terms
References
- ↑ Prescriber's Letter 11(2):10 2004 Features of Available Triptans Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200206&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Prescriber's Letter 18(6): 2011 Comparison of Available Triptans Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270610&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Loder E. Triptan therapy in migraine. Engl J Med. 2010 Jul 1;363(1):63-70 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20592298
- ↑ 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 17, 18 American College of Physicians, Philadelphia 2015, 2018
- ↑ 5.0 5.1 Paauw DS Dangerous and Deadly Drug Combinations Medscape. June 30, 2016 http://www.medscape.com/features/slideshow/dangerous-drug-combinations
- ↑ 6.0 6.1 Wang Z, VanderPluym JH, Halker Singh RB et al. Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease: A Target Trial Emulation. Mayo Clin Proc. 2024 Aug 29:S0025-6196(24)00164-2 PMID: https://www.ncbi.nlm.nih.gov/pubmed/39207344 https://www.mayoclinicproceedings.org/article/S0025-6196(24)00164-2/fulltext
- ↑ Serotonin 5-HT-Receptor Agonists Medscape (alphabetical listing) https://reference.medscape.com/drugs/serotonin-5-ht-receptor-agonists